Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 111 of the 124 references it cites were found in a registry or an index; 80 of the 161 sources its claims cite were checked for support.

What is the pipeline for future medications for obesity?

Open access
Melson, Eka, Ashraf, Uzma, Papamargaritis, Dimitris, Davies, Melanie J. · 2025 · International Journal of Obesity

Abstract

Obesity pipeline review. Semaglutide 2.4mg results in 15-17% weight loss. Tirzepatide leads up to 22.5% WL in phase 3. Retatrutide (GLP-1/GIP/glucagon RA) progressed to phase 3 trials. Early data suggests retatrutide may lead to even greater WL than tirzepatide.

Overview

CoChat Summary

## TL;DR

This review maps the rapidly expanding obesity drug pipeline, emphasizing that combinations of entero-pancreatic hormones are producing weight loss that can approach bariatric surgery. It highlights tirzepatide as the first approved dual agonist for chronic weight management and notes several oral, dual, and triple agonists in late-phase development.

## Key findings

  • Semaglutide 2.4 mg once weekly, an approved GLP-1 receptor agonist, produces 15–17% mean weight loss and has evidence of cardioprotection; the SELECT trial reported a 20% reduction in major adverse cardiovascular events (MACE) vs placebo after 39.8 months of follow-up.
  • In obesity without T2D, oral semaglutide 50 mg produced 17.4% weight loss vs 1.8% with placebo at 68 weeks in OASIS-1; in T2D, it produced 9.8% weight loss vs 5.4% with oral semaglutide 14 mg and reduced HbA1c by −2.1% vs −1.3% at 68 weeks.
  • Tirzepatide (dual GLP-1/GIP agonist) achieved 16–22.5% mean weight loss at 72 weeks in SURMOUNT-1 and up to 15.7% in SURMOUNT-2; in SURMOUNT-4, participants maintained/continued to lose weight, with 25.9% of placebo vs 84.1% of tirzepatide participants achieving ≥15% weight loss at 88 weeks from baseline.
  • Retatrutide (triple GLP-1/GIP/glucagon agonist) produced up to 24.2% weight loss at 48 weeks in a phase 2 obesity study; 36–48% of participants on the 8 mg and 12 mg doses achieved ≥25% weight loss.

## Methods

  • Narrative review of the pipeline of obesity pharmacotherapies, with a focus on entero-pancreatic hormone-based molecules and selected non-hormonal agents.
  • Synthesizes data from early- and late-phase clinical trials in people with and without T2D, and also considers effects on glycaemia, liver fat content (MASLD/MASH), and cardiovascular outcomes.
  • Main analysis is descriptive comparison of efficacy, safety, and development stage across agents; Not stated in the paper as a formal systematic review or meta-analysis.

## Limitations

  • The paper states that the full potential benefits and risks of the new obesity pharmacotherapies still need to be better understood, and that robust cost-effectiveness data are lacking.
  • It explicitly notes that cardiovascular outcome trials are still needed for several agents, including combinations of GLP-1 with other hormones and oral GLP-1 receptor agonists.
  • Evident from the text: much of the pipeline relies on phase 1/2 data, press releases, or abstract data, so some reported efficacy and safety findings are preliminary (say which: evident from the text).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41366-024-01473-y

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Secretion and main actions of the gut hormones used in the pipeline obesity treatments. GLP-1 glucagon like peptide-1, GIP glucose-dependent insulinotropic polypeptide, PYY peptide YY, *data mainly from animal studies.
Fig. 1 Secretion and main actions of the gut hormones used in the pipeline obesity treatments. GLP-1 glucagon like peptide-1, GIP glucose-dependent insulinotropic polypeptide, PYY peptide YY, *data mainly from animal studies.CC BY · PubMed Central
Fig. 2 Glucagon-like peptide-1 as the backbone of the pipeline for gut hormone-based obesity treatments. GLP-1 glucagon like peptide-1, GIP glucose-dependent insulinotropic polypeptide, PYY peptide YY, NN: novo nordisk, *completed phase 3 trials for obesity.
Fig. 2 Glucagon-like peptide-1 as the backbone of the pipeline for gut hormone-based obesity treatments. GLP-1 glucagon like peptide-1, GIP glucose-dependent insulinotropic polypeptide, PYY peptide YY, NN: novo nordisk, *completed phase 3 trials for obesity.CC BY · PubMed Central
Fig. 3 Weight loss with the obesity pharmacotherapies pipeline in people without diabetes. A Mean % weight loss, B Proportion of people achieving ≥10% weight loss, C Proportion of people achieving ≥15% weight loss. OD once daily, OW once weekly, PO oral, SC subcutaneous, GLP-1 glucagon like peptide-1, GIP glucose-dependent insulinotropic polypeptide, GCG glucagon, PBO placebo, LIRA liraglutide, SEMA semaglutide, WL weight loss, NR not reported or not available. Afor efficacy estimand data, Bmain analysis presented, as efficacy estimand not available, Cunclear whether efficacy estimand or treatment-regimen estimand, *data from published abstract, presentation, clinicaltrial.gov or from press-release by the manufacturing company, **estimated treatment difference.
Fig. 3 Weight loss with the obesity pharmacotherapies pipeline in people without diabetes. A Mean % weight loss, B Proportion of people achieving ≥10% weight loss, C Proportion of people achieving ≥15% weight loss. OD once daily, OW once weekly, PO oral, SC subcutaneous, GLP-1 glucagon like peptide-1, GIP glucose-dependent insulinotropic polypeptide, GCG glucagon, PBO placebo, LIRA liraglutide, SEMA semaglutide, WL weight loss, NR not reported or not available. Afor efficacy estimand data, Bmain analysis presented, as efficacy estimand not available, Cunclear whether efficacy estimand or treatment-regimen estimand, *data from published abstract, presentation, clinicaltrial.gov or from press-release by the manufacturing company, **estimated treatment difference.CC BY · PubMed Central
Fig. 4 HbA1c reduction and weight loss in people with type 2 diabetes with the pipeline molecules for obesity management. A Mean HbA1c change, B Mean % weight loss, C Proportion of people achieving ≥10% weight loss. OD once daily, OW once weekly, BW twice weekly, PO oral, SC subcutaneous, IV intravenous, T2DM type 2 diabetes, GLP-1 glucagon like peptide-1, GIP glucose-dependent insulinotropic polypeptide, GCG glucagon, ACVR2B activin receptor type 2B, PBO: placebo, SEMA semaglutide, DULA dulaglutide, CAGR cagrilintide, WL weight loss, NA not available, NR not reported. Afor efficacy estimand data, Bmain analysis presented, as efficacy estimand not available, *data from published abstract, presentation, clinicaltrial.gov or from press-release by the manufacturing company.
Fig. 4 HbA1c reduction and weight loss in people with type 2 diabetes with the pipeline molecules for obesity management. A Mean HbA1c change, B Mean % weight loss, C Proportion of people achieving ≥10% weight loss. OD once daily, OW once weekly, BW twice weekly, PO oral, SC subcutaneous, IV intravenous, T2DM type 2 diabetes, GLP-1 glucagon like peptide-1, GIP glucose-dependent insulinotropic polypeptide, GCG glucagon, ACVR2B activin receptor type 2B, PBO: placebo, SEMA semaglutide, DULA dulaglutide, CAGR cagrilintide, WL weight loss, NA not available, NR not reported. Afor efficacy estimand data, Bmain analysis presented, as efficacy estimand not available, *data from published abstract, presentation, clinicaltrial.gov or from press-release by the manufacturing company.CC BY · PubMed Central

Verification

Claims the paper makes

66 Valid · 1 Not valid · 63 Not checked · 13 Own results and interpretations

64 more claims · 25 with their cited sources checked

Create a free account to see all 143 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 71
  • Probably not a substantial claim. 7

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

12 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 124 references

Research works printed but not linked: 2

  1. Pfizer announces topline phase 2b results of oral GLP-1R agonist, danuglipron, in adults with obesity | Pfizer. 2023. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-2b-results-oral-glp-1r
  2. Pfizer Provides Update on GLP-1-RA clinical development program for adults with obesity and type 2 diabetes mellitus | Pfizer. 2023. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-glp-1-ra-clinical-development

Cited by

See all 332

Metadata

Authors
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J.
Affiliations
University of Leicester (GB)
Corresponding author
Papamargaritis, Dimitris
Venue
International Journal of Obesity
Published
2024-02-01
Volume
49
Issue
3
Pages
433-451
ISSN
  • 0307-0565 (ISSN-L)
  • 1476-5497
OpenAlex
W4391440666
Cited by
332
References
124
Citations by year
2026: 100 · 2025: 155 · 2024: 76
FWCI
20.67
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Obesity (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Institute for Health and Care Research (ACF-2022-11-007)
  • NIHR Leicester Biomedical Research Centre
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
obesity pharmacotherapy, GLP-1 receptor agonists, semaglutide, tirzepatide, GIP receptor agonist, glucagon, amylin, retatrutide, bimagrumab, weight loss, drug development pipeline, gut-brain axis
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Glucagon-Like Peptides, Humans, Obesity, Anti-Obesity Agents, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: What is the pipeline for future medications for obesity? https://app.cochat.ai/papers/10.1038/s41366-024-01473-y
The paper
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025). What is the pipeline for future medications for obesity? International Journal of Obesity. https://doi.org/10.1038/s41366-024-01473-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.